Abstract

BackgroundGut microbiota and microbe-derived metabolites are involved in the development of HCC. Bile acids (BAs) are the most important gut microbiota-modulated endogenous signaling molecules.MethodsWe tested serum bile acid levels and gut microbiome compositions in patients with HCC, chemical-induced HCC mouse models (DEN-HCC mice) and mouse orthotopic implanted liver tumor models with vancomycin treatment (vancomycin-treated mice). Then, we screened an important kind of HCC-related BAs, and verified its effect on the growth of HCC in vivo and in vitro.ResultsWe found that the remarkably decreasing percentages of serum secondary BAs in the total bile acids of patients and DEN-HCC mice, especially, conjugated deoxycholic acids (DCA). The relative abundance of the bile salt hydrolase (BSH)-rich bacteria (Bifidobacteriales, Lactobacillales, Bacteroidales, and Clostridiales) was decreased in the feces of patients and DEN-HCC mice. Then, in vancomycin-treated mice, vancomycin treatment induced a reduction in the BSH-rich bacteria and promoted the growth of liver tumors. Similarly, the percentage of conjugated DCA after vancomycin treatment was significantly declined. We used a kind of conjugated DCA, Glyco-deoxycholic acid (GDCA), and found that GDCA remarkably inhibited the growth of HCC in vivo and in vitro.ConclusionsWe conclude that the remarkably decreasing percentages of serum conjugated DCA may be closely associated with HCC, which may be induced by the reducing gut BSH-rich bacteria. The mechanisms may be correlated with conjugated DCA directly inhibiting the growth and migration of HCC cells.

Highlights

  • Hepatocellular carcinoma (HCC) is still the fourth most common cause of cancer-related deaths, with nearly 800,000 new cases annually, despite many recent advances in the diagnosis and treatment of hepatocellular carcinoma (HCC) [1,2,3,4]

  • chenodeoxycholic acid (CDCA) is further converted to muricholic acid (MCA) and the murine primary Bile acids (BAs) are CA and MCA(α-MCA and β-MCA) [20]

  • In mice tauro-conjugated CA and CDCA are deconjugated via bile salt hydrolases (BSH) and 7α‐dehydroxylated to form secondary BAs (DCA and lithocholic acid (LCA))

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is still the fourth most common cause of cancer-related deaths, with nearly 800,000 new cases annually, despite many recent advances in the diagnosis and treatment of HCC [1,2,3,4]. The gut microbiota can promote the development of HCC through the gut-liver axis in animal models [12, 13], and probiotics can inhibit the growth and tumor angiogenesis of HCC by regulating the gut bacteria of mice [14]. Results We found that the remarkably decreasing percentages of serum secondary BAs in the total bile acids of patients and DEN-HCC mice, especially, conjugated deoxycholic acids (DCA). In vancomycin-treated mice, vancomycin treatment induced a reduction in the BSH-rich bacteria and promoted the growth of liver tumors. Conclusions We conclude that the remarkably decreasing percentages of serum conjugated DCA may be closely associated with HCC, which may be induced by the reducing gut BSH-rich bacteria. The mechanisms may be correlated with conjugated DCA directly inhibiting the growth and migration of HCC cells

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call